Overview

Safety and Tolerability Study of Drug to Treat Schizophrenia

Status:
Completed
Trial end date:
2003-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety of SM-13496 in patients with schizophrenia.
Phase:
Phase 2
Details
Lead Sponsor:
Sunovion
Treatments:
Lurasidone Hydrochloride